Raj Mehta

Raj has over 20 years’ experience in partnering early stage technologies and leading formation of spin-out companies. He spent 18 years at Cancer Research Technology where he led portfolio management of biological and small molecule therapeutic assets and creation of BliNK Therapeutics, Revitope Limited (now a subsidiary of Revitope Oncology), FastBase Solutions and GammaDelta Therapeutics.

He served as interim CEO of GammaDelta Therapeutics where he led on establishing a transformative partnership with Takeda and is currently the Director of Intellectual Property, Alliance Management and Business Development. Prior to joining Cancer Research Technology, Raj was Group Leader in the E. Merck Laboratory at MRC Collaborative Centre (London) leading groups supporting anti-angiogenesis and cardiovascular drug discovery projects for Merck KGaA (Darmstadt).